Durability of SARS-CoV-2 mRNA Booster Vaccine Protection Against Omicron Among Health Care Workers with a Vaccine Mandate.

ABSTRACT:

Background

The SARS-CoV-2 Omicron Variant has spread rapidly throughout the world since being identified in South Africa in November 2021. Few studies have assessed primary series and booster vaccine effectiveness against Omicron among US health care workers.

Methods

We conducted a test-negative case-control design to estimate BNT162b2 and mRNA1273 primary vaccination and booster effectiveness against SARS-CoV-2 infection and symptomatic Covid-19 during an Omicron surge among employees of the University of Pennsylvania Health System. The study period was between 7/1/21-4/5/22. We defined the Delta period as 7/1/21-12/12/21 and the Omicron period as beginning 12/20/21.

Results

Our sample included 14,520 tests (2,776 [19%] positive)-7,422 (506 [7%] positive) during Delt

SUBMITTER: Richterman A 

PROVIDER: S-EPMC9214168 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature